AKEBIA THERAPEUTICS, INC.
Last · —$0.702-0.068 (-8.83%)live · yahoo · 1h ago
Market cap$194.53M—
P/E · TTM—fwd — · eps —
Beta—vs S&P 500
Div yield—annual · TTM
52w range
——
Volume—session
| Revenue | $219.1M |
|---|---|
| Operating income | $-11.0M |
| Net income | $-18.0M |
| Free cash flow | $40.3M |
| Operating margin | -5.0% |
| Net margin | -8.2% |
| Return on equity | -71.8% |
| Period | TTM 2026-06-30 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-02-26
- Accumulated Deficit High
Red flags
- Accumulated Deficit High — Accumulated deficit / equity 5163%
Upcoming earnings
9:00 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.03
Est. revenue
46.9M
Press & signals
- GlobeNewswire
Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
- GlobeNewswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Satelight
Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags